



Emerging Therapies Workgroup Overview

December 18, 2019

Judy Zerzan, Medical Director

Workgroup's Scope

- ▶ Workgroup is charged with helping HCA identify concerns, ethics, and perspectives around emerging therapies.
- ▶ Issues related to Emerging Therapies:
 - ▶ Long-term funding
 - ▶ Quality oversight and outcome tracking
 - ▶ Management of patients eligible for emerging therapies
 - ▶ Potential improvements to health outcomes and quality of life
 - ▶ Potential long-term savings or expenditures to the state
 - ▶ Metrics that could be used to measure the fiscal and health impacts

Meeting Schedule

June 18, 2019	<ul style="list-style-type: none"> • Overview of new therapies coming to market • Private sector perspective on managing emerging therapies • HCA/Medicaid perspective on managing emerging therapies • Current financing 	Invitation only
October 18, 2019	<ul style="list-style-type: none"> • Patient decision aids • Patient experience • Patient advocates present 	Invitation only
December 18, 2019	<ul style="list-style-type: none"> • Summary of the workgroup's progress so far • Stakeholder questions and comments 	Open public meeting
February 19, 2020	<ul style="list-style-type: none"> • Long-term funding for emerging therapies • Potential funding options between manufacturers and the state • Different payment options between the state and managed care organizations 	Open public meeting
April 15, 2020	<ul style="list-style-type: none"> • Potential improvements and harms to health outcomes and quality of life for patients • Quality oversight and outcome tracking of providers and facilities administering emerging therapies • Metrics that could be used to measure the fiscal and health impacts of emerging therapies • Potential long-term savings and expenditures to the state 	Invitation only
June 9, 2020	<ul style="list-style-type: none"> • Summary of the workgroup's progress • Stakeholder questions and feedback • Next steps 	Open public meeting

Recap of June 18th Meeting

Growth in Specialty Drugs

2008

About 10 years ago, specialty medicines accounted for **24.7%** of total pharmacy spending

2017

Today, they contribute to **46.5%** of total pharmacy spending, but only **~2% of prescriptions**

Pipeline

▶ Breakthrough specialty drugs

- Certain types of cancer
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Spinal Muscular Atrophy
- Nonalcoholic Steatohepatitis
- Blindness (neovascular age-related macular degeneration)
- Hemophilia
- Alzheimer's disease
- Certain neurologic diseases

Pipeline (cont.)

▶ Of the drugs now in Phase III trials...

- 60% are specialty drugs
- 33% are orphan drugs
- 13% are considered breakthrough therapies
- Only 8% are biosimilars

▶ Of the applications submitted to the FDA...


- 25% of new drug applications submitted to the FDA have been granted “priority review”

Current Approaches to Determining Coverage

Similarities between Commercial Insurers and WA Health Care Authority:

- ▶ Evaluation of evidence
- ▶ Budget/Financial impact analysis
- ▶ Development of clinical criteria
- ▶ Tracking outcomes

Decisions are Complex and Affected by Perspective



- ▶ What the decision-makers value and how they value it is a complex inter-relationship of what matters within the organization and who they serve.
- ▶ The decision-making criteria are shared though elements of it may be weighted or valued differently.

Henshall, C. Schuller, T., **Health Technology Assessment, Value-based Decision Making and Innovation.**, International Journal of Technology Assessment in Health Care, 29:4 (2013), 353-359.

Workgroup's Discussion

▶ Cost, Quality & Access

- ▶ What are the levers we have?
- ▶ Reinsurance options with orphan drugs
- ▶ Best price implications
- ▶ Societal impact
- ▶ Outcome-based contracts
- ▶ Long term side-effects
- ▶ Cure vs. maintenance (patient perspective -- disease by disease)
- ▶ Patient decision aids
- ▶ Outcome registry
- ▶ Provider education
- ▶ Informed consent
- ▶ Alternative treatments

Recap of October 18th Meeting

Patient Advocate Presentations

▶ Parkinson's Disease

▶ Hemophilia

▶ Sickle Cell

- ▶ Per your specialty, what drugs are in the pipeline that your organization is aware of and tracking?
- ▶ How does your organization evaluate new drugs? Curative? Safety? Efficacy? Benefits?
- ▶ How does (or would) your organization define a cure?
- ▶ How does your organization educate patients/families about treatment options?

Perspectives on Educating & Guiding Patients to Treatment Decisions

▶ Pediatric cancer specialist

- ▶ What are some of the biggest challenges and best practices from a physician perspective when educating and guiding families on treatment decisions for children?
- ▶ How do you talk to patients about therapies that have uncertain benefits?
- ▶ How much information do you need to know about an emerging therapy before you will discuss it with a patient?

▶ Oncologist specialized in blood and marrow (stem cell)

- ▶ What are some of the biggest challenges and best practices from a physician perspective when educating and guiding adult patients on their own treatment decisions?
- ▶ How do you talk to patients about therapies that have uncertain benefits?
- ▶ How much information do you need to know about an emerging therapy before you will discuss it with a patient?

▶ Patient decision aids

- ▶ What are the best practices when using PDAs?
- ▶ What is shared decision making?

Ethical Considerations for Emerging Therapies

- ▶ Health payer policy decisions
- ▶ Personal patient decisions
- ▶ Medical necessity
- ▶ Process of health care decision-making
- ▶ Benefits & harms of treatment

Take aways

- ▶ Glad Pharma will be represented. Multiple drug view points useful.
- ▶ FDA approval, how benefitting are drugs?
- ▶ Cost containment.
- ▶ Access, equity.
- ▶ Visibility
- ▶ Funding option challenges
- ▶ How does Pharma determine cost? Pharma come prepared, price transparency.
- ▶ Senator Murray's office- funding
- ▶ How do we ensure all stakeholders continue to be part of conversation?
- ▶ Pharma says pay over 5 yrs. Payers will not be part of.
- ▶ Reinsurance, risk corridor
- ▶ Cost to one versus savings to another
- ▶ Bills in legislation
- ▶ Education, shared decision making

Questions & Comments

- ▶ Email: HCAEmergingTherapies@hca.wa.gov
- ▶ Website: <https://www.hca.wa.gov/about-hca/clinical-collaboration-and-initiatives/emerging-therapies-workgroup>